51552-68-2

Basic information

• Product Name: Methyl 7-quinolinecarboxylate
• Synonyms: Methyl 7-quinolinecarboxylate;Methyl quinoline-7-carboxylate;Quinoline-7-carboxylic acid methyl ester;7-Quinolinecarboxylic acid, methyl ester
• CAS NO: 51552-68-2
• Molecular Formula: C₁₁H₉NO₂
• Molecular Weight: 187.19466
• Mol File: 51552-68-2.mol

Chemical Properties

• Boiling Point: 315.1±15.0 °C(Predicted)
• Appearance: /
• Density: 1.210±0.06 g/cm3(Predicted)
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 2.95±0.14(Predicted)
• CAS DataBase Reference: Methyl 7-quinolinecarboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: Methyl 7-quinolinecarboxylate(51552-68-2)
• EPA Substance Registry System: Methyl 7-quinolinecarboxylate(51552-68-2)

Safety Data

• Hazardous Substances Data: 51552-68-2(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical and Agrochemical Industries:
Methyl 7-quinolinecarboxylate is used as a building block for the synthesis of various pharmaceuticals and agrochemicals. Its unique structure and functional group contribute to the development of new compounds with therapeutic and pesticidal properties.
Used in Chemical and Biological Research:
Methyl 7-quinolinecarboxylate is used as a fluorescence probe in chemical and biological research. Its fluorescent properties allow for the tracking and visualization of specific molecules or processes, aiding in the study of various biological and chemical phenomena.
Used in Antimicrobial and Antiviral Applications:
Methyl 7-quinolinecarboxylate has been studied for its potential antimicrobial and antiviral properties. Its ability to inhibit the growth of certain microorganisms and viruses makes it a promising candidate for the development of new antimicrobial and antiviral agents.

Upstream product

• 186581-53-3 diazomethane 
• 1078-30-4 quinoline-7-carboxylic acid 
• 67-56-1 methanol 
• 4965-36-0 7-bromoquinoline 
• 201230-82-2 carbon monoxide 
• 346-55-4 4-chloro-7-trifluoromethyl quinoline 
• 325-14-4 7‐(trifluoromethyl)quinoline 

Downstream Products

• 1078-30-4 quinoline-7-carboxylic acid 
• 597562-79-3 methyl 1,2,3,4-tetrahydroquinoline-7-carboxylate 
• 49713-58-8 4‐chloroquinoline‐7‐carboxylic acid 
• 1150618-22-6 4-hydroxyquinoline-7-carboxylic acid 
• 178984-69-5 7-Methyloxycarbonyl-4-chloroquinoline 
• 1416801-65-4 methyl 2-chloro-quinoline-7-carboxylate 
• 1034776-74-3 1-(2-methoxy-5-methyl-benzenesulfonyl)-1,2,3,4-tetrahydro-quinoline-7-carboxylic acid methyl ester 
• 1034776-76-5 1-(2-methoxy-5-methyl-benzenesulfonyl)-1,2,3,4-tetrahydro-quinoline-7-carboxylic acid 
• 49573-30-0 quinoline-7-carbaldehyde 
• 1451154-40-7 methyl 2-methoxyquinoline-7-carboxylate 
• 1374258-40-8 2-methoxyquinoline-7-carboxylic acid 
• 188874-61-5 7-bromomethyl-quinoline hydrobromide 

Relevant articles and documents

TARGETED RADIOPHARMACEUTICALS FOR THE DIAGNOSIS AND TREATMENT OF PROSTATE CANCER

A compound of general formula (I): wherein: n is 1, 2 or 3; R1, R2, R3 and R4, independently represent OH or Q; and 20 Q represents a tissue-targeting moeity selected from the group consisting of or a stereoisomer, a hydrate, a solvate, or a salt thereof, or a mixture of same, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said 25 compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of soft tissue diseases, as a sole agent or in combination with other active ingredients.

TRPM8 ANTAGONISTS AND THEIR USE IN TREATMENTS

Compounds of Formula (I) are useful as antagonists of TRPM8. Such compounds are useful in treating a number of TRPM8 mediated disorders and conditions and may be used to prepare medicaments and pharmaceutical compositions useful for treating such disorders and conditions. Examples of such disorders include, but are not limited to, migraines and neuropathic pain. Compounds of Formula (I) have a structure where the definitions of the variables are provided herein.

N1/N2-Lactam Acetyl-CoA carboxylase inhibitors

The invention provides a compound of Formula (I) or a pharmaceutically acceptable salt thereof; wherein G is R1, R2 and R3 are as described herein; pharmaceutical compositions thereof; and the use thereof in treating diseases, conditions or disorders modulated by the inhibition of an acetyl-CoA carboxylase enzyme(s) in an animal

Substituted Spiroamide Compounds

Substituted spiroamide compounds corresponding to formula (I): wherein A, B, Q1, Q2, Q3, Q4, R1, R8, R9a, R9b, R12, R13, R200 and R210 have defined meanings, processes for their preparation, pharmaceutical compositions containing such compounds, and the use of such compounds for treating or inhibiting pain or other conditions mediated at least in part by the bradykinin 1 receptor (B1R).

2-Cyanophenyl fused heterocyclic compounds, and compositions and uses thereof

Fused heterocyclic compounds are provided according to formula 1: where R1, R2, R3, and m are as defined herein. Provided compounds and pharmaceutical compositions thereof are useful for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, pain, inflammation, cognitive disorders, anxiety, depression, and others.

The discovery and preparation of disubstituted novel amino-aryl-piperidine- based renin inhibitors

Recently, trans-disubstituted oxo-aryl-piperidines have been identified as small molecule nonpeptide renin inhibitors for the modulation of hypertension. Herein, we report on the discovery and preparation of a new class of novel cis-disubstituted amino-aryl-piperidines as a mixture of enantiomers that are potent in vitro renin inhibitors and also, possess in vivo antihypertensive activity in a double transgenic mouse model.

Piperidine derivative rennin inhibitors

Disclosed are piperidine derivatives, their manufacture and use as inhibitors of renin.

Piperidine-renin inhibitors compounds with improved physicochemical properties

Piperidine renin inhibitors with heterocyclic core modifications or hydrophilic attachments show improved physical properties (lower lipophilicity, improved solubility). Tetrahydroquinoline derivative rac-30 with a molecular weight of 517 and a log D((pH 7.4)) of 1.9 displays potent and long lasting blood pressure lowering effects after oral administration to sodium depleted conscious marmosets.